KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.

Cynthia Levy, David E J Jones, Marlyn J Mayo, Christopher L Bowlus, Kris V Kowdley, Gideon M Hirschfield, Jie Liu, Caroline Burk, Susheela Carroll, Daria B Crittenden, Andreas E Kremer

Aliment Pharmacol Ther 64(1) 23-35

PMID41933275
PMCIDPMC13251588
DOI10.1111/apt.70630
发表日期2026-04-03
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 multi panel km;FIGURE 2:AI 判定为 other;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图;另有 1 张未列出。
摘要

摘要

BACKGROUND: Pruritus and fatigue impose a significant burden on patient quality of life in primary biliary cholangitis (PBC). In the Phase 3 RESPONSE trial (NCT04620733), seladelpar, a potent and selective PPARδ agonist, significantly improved markers of cholestasis and pruritus. AIMS: Here, we provide additional details on the effects of seladelpar on pruritus and quality of life. METHODS: In RESPONSE, patients with PBC and an inadequate response or intolerance to ursodeoxycholic acid were randomised 2:1 to seladelpar 10 mg or placebo for 12 months. Changes in severity of pruritus by the numeric rating scale (NRS) and changes in 5-D Itch and PBC-40 in patients with moderate to severe itch (NRS ≥ 4), severe itch (NRS ≥ 7) and clinically significant itch (PBC-40 itch ≥ 7) at baseline were evaluated. RESULTS: In patients with baseline NRS ≥ 4, mean NRS improved from the moderate to mild range with seladelpar, but not placebo. Bodily distribution of itch was reduced with seladelpar based on the 5-D itch distribution domain. Itch-related sleep disturbance was consistently improved with seladelpar across populations, and measures of fatigue were improved versus placebo in patients with severe itch at baseline. Patients without itching tended to remain free from itching with seladelpar, consistent with fewer adverse events of pruritus with seladelpar versus placebo. CONCLUSION: In addition to an established anticholestatic effect, seladelpar improved pruritus severity and distribution, itch-related sleep disturbance and measures of fatigue in patients with PBC and pruritus, indicating clinically relevant improvements in itch and other quality of life benefits.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Mean pruritus NRS over time (A), percentage of patients with a ≥ 3‐point NRS decline at 6 and 12 months (B), percentage of patients with a ≥ 4‐point NRS decline at 6 and 12 months (C) and percentage of patients with near resolution of itch (NRS = 0–1) (D) in patients with moderate to severe pruritus based on NRS ≥ 4 at BL. A colour‐blind accessible version of panel (A) is available in Figure S8 . In panel (A), n = the number of patients who had both a BL value and a value at that time point. In panels (B–D), patients with missing data at the specific time point were considered nonresponders. BL, baseline; NRS, numeric rating scale.
非 KM Figure
FIGURE 2Daily duration of itch (A) and body regions with pruritus (B) over time based on 5‐D Itch in patients with moderate to severe pruritus based on NRS ≥ 4 at BL. Colour‐blind accessible versions of panels (A) and (B) are available in Figure S9 . ‡ In panel (A), the symbol represents 2% ( n = 1). † In panel (A), the symbol represents 3% ( n = 1). In panel (A), n = the number of patients who had both a BL value and a value at that time point. In panel (B), percentages represent the number of patients who reported itching in that body region at that analysis visit divided by the number of patients who had a value in that body region at that analysis visit (m). BL, baseline; NRS, numeric rating scale.
非 KM Figure
FIGURE 3Change from BL in mean pruritus NRS over time (A) and percentage of patients with near resolution of itch (NRS = 0–1) (B) in patients with severe pruritus based on NRS ≥ 7 at BL. **In panel (A), p < 0.05 versus placebo. In panel (A), change from BL was estimated by a mixed‐effects model for repeated measures. n = the number of patients who had both a BL value and a value at that time point. In panel (B), patients with missing data at the specific time point were considered nonresponders. BL, baseline; LS, least‐square; NRS, numeric rating scale.
非 KM Figure
FIGURE 4Change in PBC‐40 itch domain (A), sleep disturbance question (B) and fatigue domain (C) in patients with severe pruritus based on NRS ≥ 7 at BL. * p < 0.001 versus placebo. ** p < 0.05 versus placebo. Change from BL was estimated by a mixed‐effects model for repeated measures. n = the number of patients who had both a BL value and a value at that time point. In panel (A), PBC‐40 Itch domain scores ranged from 0 to 15. In panel (B), PBC‐40 sleep disturbance question (within the itch domain) scores ranged from 0 to 5. In panel (C), PBC‐40 fatigue domain scores ranged from 11 to 55. BL, baseline; LS, least‐square; NRS, numeric rating scale; PBC, primary biliary cholangitis.
非 KM Figure
FIGURE 5Change in PBC‐40 itch domain (A), sleep disturbance question (B) and fatigue domain (C) in patients with clinically significant pruritus based on PBC‐40 Itch ≥ 7 at BL. * p < 0.001 versus placebo. ** p < 0.05 versus placebo. Change from BL was estimated by a mixed‐effects model for repeated measures. n = the number of patients who had both a BL value and a value at that time point. In panel (A), PBC‐40 itch domain scores ranged from 0 to 15. In panel (B), PBC‐40 sleep disturbance question (within the itch domain) scores ranged from 0 to 5. In panel (C), PBC‐40 fatigue domain scores ranged from 11 to 55. BL, baseline; LS, least‐square; PBC, primary biliary cholangitis.
非 KM Figure
FIGURE 6Sankey plot of BL and month 12 NRS categories for seladelpar and placebo in overall study population. A colour‐blind accessible version of this figure is available in Figure S10 . Categories were defined as: No or near no itch (NRS = 0–1), mild (NRS > 1 to < 4), moderate (NRS 4 to < 7), or severe itch (NRS ≥ 7). Includes patients with data available at both BL and 12 months. BL, baseline; NRS, numeric rating scale.
非 KM Figure